Klinikum Bayreuth GmbH — Clinical Trial Site

36 Registered trials

15 Currently recruiting

Organisation

Klinikum Bayreuth GmbH

Location

Bayreuth, Germany

Identifier

ORG-100043903

Address

Preuschwitzer Straße 101, Roter Hügel, 95445, Germany

Departments

"Betriebsstaette Klinik Hohe Warte Neurologische Klinik"
#2048:Hämatologie und internistische Onkologie
04908: Frauenklinik & Brustzentrum
6713: Hohe Warte, Neurologische Klinik
Clinic for Gynecology and Obstetrics
Department of Anesthesiology and Intensive Care Medicine
Dept. of Neurology
Frauenklinik
Hämatologie und internistische Onkologie
Hämatologie/Internist. Onkologie
Hematology
Innere Medizin, Schwerpunkt Hämatologie und Internistische Onkologie
Klinik fuer Neurologie
Klinik fuer Querschnittgelaehmte
Klinik fur Neurologie
Klinik für Neurologie; Klinik Hohe Warte Bayreuth
Klinik für Onkologie und Hämatologie
Klinik und Institut für Strahlentherapie
Klinikum Bayreuth GmbH
Med. Klinik IV
Med. Klinik IV - Innere Medizin
Medizinische Klinik IV
Medizinische Klinik IV/Innere Medizin Hämatologie und internistische Onkologie
Neurology
Studienzentrum Klinik fuer Neurologie

Clinical trials at this site (36)

Search interface

A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into… Not authorised

2022-501644-15-00 Mild Cognitive Impairment due to Alzheimer's Disease Al 4
Stopping tyrosine kinase inhibitors a second or third time after unsuccesful treatment discontinuation in chronic myeloid leukemia Pending

2024-519472-69-00 CML-Patients in chronic phase having failed a prior att 4
A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower-risk MDS in ESA-naïve adults who require RBC … Pending

2025-523544-12-00 Myelodysplastic neoplasms/syndromes (MDS) 5
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518006-40-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-13
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
Evaluating the clinical effectiveness of sodium bicarbonate for critically ill patients with metabolic acidosis and acute kidney injury Recruiting

2025-523914-10-00 Critical illness 6 2026-04-30
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting

2024-516966-12-00 Alzheimer’s disease 4 2026-02-13
A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518008-33-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-12
Clinical study to evaluate the safety and tolerability of long-term treatment with Lecicarbon® in patients with chronic constipation Recruiting

2025-522464-32-00 Treatment of chronic constipation 6 2025-09-09
A first-in-human (FIH) clinical trial to investigate the human monoclonal antibody NG004, administrated intrathecally in acute spinal cord i… Recruiting

2024-514303-34-00 Acute Incomplete Cervical Spinal Cord Injury 1 2024-12-18
Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in … Recruiting

2023-504925-38-00 patients with hormone receptor (HR)-positive, HER2-nega 4 2024-12-10
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran… Recruiting

2024-512878-98-00 Brain Metastasis from Estrogen Receptor Positive, HER-2 9 2023-05-16
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trif… Recruiting

2024-513723-16-00 metastatic colorectal cancer 4 2021-10-21
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended

2024-513540-29-00 Breast Cancer 5 2024-11-07
A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended

2023-510178-15-00 High-risk Large B-cell Lymphoma 5 2024-07-31
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended

2022-501644-15-01 Mild Cognitive Impairment due to Alzheimer's Disease Al 4 2023-09-28
Phase 3 Clinical Trial of Gedatolisib in Patients with HR Positive, HER2 Negative Advanced or Metastatic Breast Cancer (VIKTORIA-1) Ended

2022-502145-10-00 Hormone Receptor (HR)-Positive, Human Epidermal Growth 5 2023-06-06
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N… Ended

2024-510947-71-00 Chronic Myeloid Leukemia 5 2022-11-21